Literature DB >> 11355290

Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant.

P K Henneberger1, D Cumro, D D Deubner, M S Kent, M McCawley, K Kreiss.   

Abstract

OBJECTIVE: Workers at a beryllium ceramics plant were tested for beryllium sensitization and disease in 1998 to determine whether the plant-wide prevalence of sensitization and disease had declined since the last screening in 1992; an elevated prevalence was associated with specific processes or with high exposures; exposure-response relationships differed for long-term workers hired before the last plant-wide screening and short-term workers hired since then.
METHODS: Current workers were asked to complete a questionnaire and to provide blood for the beryllium lymphocyte proliferation test (BeLPT). Those with an abnormal BeLPT were classified as sensitized, and were offered clinical evaluation for beryllium disease. Task- and time-specific measurements of airborne beryllium were combined with individual work histories to compute mean, cumulative, and peak beryllium exposures for each worker.
RESULTS: The 151 participants represented 90% of 167 eligible workers. Fifteen (9.9% of 151) had an abnormal BeLPT and were split between long-term workers (8/77 = 10.4%) and short-term workers (7/74 = 9.5%). Beryllium disease was detected in 9.1% (7/77) of long-term workers but in only 1.4% (1/74) of short-term workers (P = 0.06), for an overall prevalence of 5.3% (8/151). These prevalences were similar to those observed in the earlier survey. The prevalence of sensitization was elevated in 1992 among machinists, and was still elevated in 1998 among long-term workers (7/40 = 18%) but not among short-term workers (2/36 = 6%) with machining experience. The prevalence of sensitization was also elevated in both groups of workers for the processes of lapping, forming, firing, and packaging. The data suggested a positive relationship between peak beryllium exposure and sensitization for long-term workers and between mean, cumulative, and peak exposure and sensitization for short-term workers, although these findings were not statistically significant. Long-term workers with either a high peak exposure or work experience in forming were more likely to have an abnormal BeLPT (8/51 = 16%) than the other long-term workers (0/26, P = 0.05). All seven sensitized short-term workers either had high mean beryllium exposure or had worked longest in forming or machining (7/55 = 13% versus 0/19, P = 0.18).
CONCLUSIONS: A plant-wide decline in beryllium exposures between the 1992 and 1998 surveys was not matched by a decline in the prevalence of sensitization and disease. Similar to findings from other studies, beryllium sensitization/disease was associated with specific processes and elevated exposures. The contrast in disease prevalence between long-term and short-term workers suggests that beryllium sensitization can occur after a short period of exposure, but beryllium disease usually requires a longer latency and/or period of exposure. The findings from this study motivated interventions to more aggressively protect and test workers, and new research into skin exposure as a route of sensitization and the contribution of individual susceptibility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355290     DOI: 10.1007/s004200100237

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  36 in total

Review 1.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 2.  Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Authors:  Richard T Sawyer; Lisa A Maier
Journal:  Biometals       Date:  2010-10-28       Impact factor: 2.949

3.  Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers.

Authors:  Kristin J Cummings; David C Deubner; Gregory A Day; Paul K Henneberger; Margaret M Kitt; Michael S Kent; Kathleen Kreiss; Christine R Schuler
Journal:  Occup Environ Med       Date:  2006-10-16       Impact factor: 4.402

4.  Exposure and dose modelling in occupational epidemiology.

Authors:  David Kriebel; Harvey Checkoway; Neil Pearce
Journal:  Occup Environ Med       Date:  2007-07       Impact factor: 4.402

5.  Beryllium's public relations problem: protecting workers when there is no safe exposure level.

Authors:  David Michaels; Celeste Monforton
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

6.  5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Authors:  Brian J Day; Jie Huang; Briana Q Barkes; May Gillespie; Li Li; Lisa A Maier
Journal:  Lung       Date:  2017-10-27       Impact factor: 2.584

7.  Efficacy of a program to prevent beryllium sensitization among new employees at a copper-beryllium alloy processing facility.

Authors:  Carrie A Thomas; Rachel L Bailey; Michael S Kent; David C Deubner; Kathleen Kreiss; Christine R Schuler
Journal:  Public Health Rep       Date:  2009 Jul-Aug       Impact factor: 2.792

8.  Progression from beryllium exposure to chronic beryllium disease: an analytic model.

Authors:  Philip Harber; Siddharth Bansal; John Balmes
Journal:  Environ Health Perspect       Date:  2009-02-27       Impact factor: 9.031

9.  Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.

Authors:  Lisa A Maier; Briana Q Barkes; Margaret Mroz; Milton D Rossman; Juliana Barnard; May Gillespie; Allison Martin; Douglas G Mack; Lori Silveira; Richard T Sawyer; Lee S Newman; Andrew P Fontenot
Journal:  Respir Med       Date:  2012-09-11       Impact factor: 3.415

10.  Long-term follow-up of beryllium sensitized workers from a single employer.

Authors:  Mona Duggal; David C Deubner; Anne M Curtis; Mark R Cullen
Journal:  BMC Public Health       Date:  2010-01-04       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.